Skip to main content
Premium Trial:

Request an Annual Quote

Kailos Expands Partnership With US DoD on Genetic Identification for Counter-Terrorism

NEW YORK (GenomeWeb) – Genetic testing firm Kailos Genetics announced today that it has expanded its existing partnership with the US Department of Defense's Combating Terrorism Technical Support Office (CTTSO).

Under the terms of the agreement, Kailos will continue developing a laboratory and software solution for analysis and identification of genetic material, for the purposes of counter-terrorism.

"Through enriching and deeply sequencing DNA samples, we can uncover information to positively impact the work being done by federal investigative agencies," Kailos CSO Troy Moore said in a statement.

The DoD established the CTTSO in 1999, with a mission to "identify and develop capabilities to combat terrorism and irregular adversaries and to deliver these capabilities to DoD components and interagency partners."

Kailos, based at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, said it reached several milestones set by the CTTSO to verify the credibility of its targeted genetic sequencing methods, including complete sequencing of hundreds of genetic samples, some of which had been genotyped by alternative methodologies.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.